logo-loader
AIM:AMYT NASDAQ:AMYT

Amryt Pharma PLC

Receive alerts
Market:
AIM
Market Cap:
£289.26 m
Price
182.50 GBX
Change
0.00%
52 weeks high
202.00
52 weeks low
80.00

WHO WE ARE

We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare and orphan diseases.

We are building an exciting portfolio of breakthrough, proprietary medicines by looking beyond the ordinary and recognising potential, where others see none.

A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity and ethical practice. We aim to forge partnerships and collaborations that work for all. By listening to our stakeholders we create a clear path for our transformative medicines to reach those that need them.

OUR TEAM

At Amryt Pharma we have an exceptional team with the collective vision to deliver medicines that are truly transformative for people with rare, debilitating illnesses.

Our leadership team offers a wealth of experience in identifying, commercialising and delivering new treatments across global markets. Our ability to navigate diverse regulatory and reimbursement environments, combining a ‘think global, act local approach’, positions us optimally to deliver our goals.

PRODUCT PORTFOLIO

Amryt Pharma is committed to delivering safe, effective and innovative medicines that treat extremely rare and life-threatening diseases; transforming lives where it may not have been possible in the past. Our portfolio of specialist therapies includes products that we plan to make available to people with rare diseases across the world.


LOJUXTA®▼ / JUXTAPID® (LOMITAPIDE)

 

MYALEPT®/ MYALEPTA® (METRELEPTIN)

 

OLEOGEL-S10 (AP101)

 

AP103 (GENE THERAPY)​​​​​​​

RAY STAFFORD

Non-executive Chairman

Mr. Stafford has worked in the pharmaceutical industry for thirty years. He was Chairman, Chief Executive Officer and majority shareholder of the Tosara Group who owned, manufactured and marketed the successful international brand Sudocrem. Tosara was integrated into the US based NYSE listed company Forest Laboratories, Inc. in 1988. Mr. Stafford held numerous senior positions within that corporation including Chief Executive Officer of Forest UK and Ireland as well as Chief Executive Officer of Forest Laboratories Europe since 1999. Mr. Stafford retired in 2014 following the sale of Forest Laboratories, Inc. to Actavis Plc (now Allergan Plc) in a US $28 billion transaction where Mr. Stafford was Executive Vice President of Global Marketing. Separately, Mr. Stafford was founder of what is today one of Ireland’s leading multi-channel sales, marketing and distribution service providers approved by the Irish Medicines Board (now The Health Products Regulatory Authority) to service the wholesale and retail trade.

 

DR. JOE WILEY

Chief Executive Officer (CEO)

Dr. Wiley founded Amryt and has over 20 years of experience in the pharmaceutical, medical and venture capital industries. Dr. Wiley opened and led the European office of Sofinnova Ventures Inc. He was previously a medical director at Astellas Pharma Limited where he liaised with the marketing team and was involved in the launch of a number of specialty pharmaceutical products. Prior to joining Astellas Pharma Limited, he held investment roles at Spirit Capital SA, Inventages Venture Capital Investment Inc. and Aberdeen Asset Managers Private Equity Limited. Dr. Wiley trained in general medicine at Trinity College Dublin, specialising in neurology. He has a Masters of Business Administration from INSEAD and is also a Member of the Royal College of Physicians in Ireland. Dr.Wiley will continue as Chief Executive Officer of the Enlarged Group for no less than two years after Closing, unless he resigns or is removed from the position by a vote of a majority of the Board

 

STEPHEN WILLS

Non-executive Director

Mr.Wills serves as the Chief Financial Officer, since 1997, and Chief Operating Officer, since 2011, of Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Mr.Wills also serves on the boards of: Caliper Corporation, since 2016; MediWound Ltd., since 2017; and Gamida Cell Ltd., since 2019. Mr.Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a public company providing advanced wound care products, from December 2015 until February 2017 when Derma Sciences, Inc. was acquired by Integra LifeSciences Holding Corporation. Mr. Wills also served as the lead director of Derma Sciences, Inc. until December 2015 and as Chief Financial Officer from 1997 to 2000. Mr. Wills is 531 Chairman of the board of trustees of The Hun School of Princeton, New Jersey and from 1991 to 2000 he was the President and Chief Operating Officer of Golomb,Wills & Company, P.C., a public accounting firm. Mr. Wills is a certified public accountant and earned his Bachelor of Science in accounting from West Chester University and a Master of Science in taxation from Temple University.

 

DR. PATRICK VINK

Non-executive Director

Dr.Vink has significant experience as a senior executive having worked in the pharmaceutical industry for more than 30 years. Dr. Vink serves as Chairman at Acacia Pharma Group plc and Targovax ASA, both publicly listed biopharma companies based in the UK and Norway. Dr. Vink also serves as Chairman of venture capital backed NMD Pharma ApS, a neurology biopharma company in Denmark and F2G Ltd, a rare fungal disease UK- and Austria-based company. In addition, Dr. Vink is a board member at Santhera AG and Spero Therapeutics Inc and since 2019 began working with Athyrium as a Senior Advisor. While serving at these companies, Dr. Vink has been involved in initial public listings, geographic expansions and contributed to the achievement of meaningful development and commercial
milestones. Earlier in his career he held several leadership positions across the industry, including Head of Global Biopharmaceuticals for the Sandoz division of the Novartis Group, Vice President International Business for Biogen Inc., and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi-Synthelabo Ltd. Dr.Vink also served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations between 2013 and 2015. He graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his Masters of Business Administration in 1992 at the University of Rochester.

 

DONALD STERN

Non-executive Director

Mr. Stern was previously a director of Novelion until September 2019, and previously a member of Aegerion’s board of directors from September 2015 through to October 2016.Mr. Stern is Managing Director of Corporate Monitoring & Consulting Services at Affiliated Monitors Inc., a consulting firm providing independent integrity monitoring services and compliance services across a wide range of regulated industries and professions. He has had a diverse and distinguished legal career, evenly split between private practice and public service. He has been a partner at three major law firms including Cooley LLP, Bingham McCutchen LLP, and Hale & Dorr LLP (now Wilmer Cutler Pickering Hale and Dorr LLP). Mr. Stern has served as the United States Attorney for the District of Massachusetts, the Chief Legal Counsel to Governor Michael S. Dukakis and the Chief of the Government Bureau in the Massachusetts Attorney General’s office. Mr. Stern holds a Masters in Laws from University of Pennsylvania Law School, a Juris Doctor degree from Georgetown University Law Center and a Bachelor of Arts from Hobart College.

 

DR. ALAIN MUNOZ

Non-executive Director

Dr. Munoz, M.D., Ph.D. is an entrepreneur and independent management consultant in the pharmaceutical and biotechnology industry, and has over 30 years of experience in the industry at the executive level. Dr. Munoz worked with the Fournier Group, as Research and Development director and then Senior Vice President of the Pharmaceutical Division. He joined the Fournier Group from Sanofi Group, where he started as director in the cardiovascular and anti-thrombotic products department and then asVice President international development. Dr.Munoz is qualified in cardiology and anaesthesiology from the University Hospital of Montpellier, France where he was head of the clinical cardiology department. He has been a member of the Scientific Committee of the French drug agency. He is advisor to Kurma Partners and serves on the scientific advisory board of Valneva SA. He is an independent board member of Hybrigenics S.A., Auris Medical Holding AG and Zealand Pharma A/S.

 

GEORGE HAMPTON JR

Non-executive Director

Mr. Hampton joined Currax Pharmaceuticals in April of 2019 as Chief Executive Officer and serves on its board of directors.  Prior to joining Currax, Mr. Hampton served as executive vice president, primary care business unit for Horizon Pharmaceuticals (HZNP), a public biopharmaceutical company.  In this role he was tasked with leading the forward-looking strategy, as well as establishing operational goals for the business.  Previously, Mr. Hampton served as executive vice president, global orphan business unit and international operations for Horizon Pharmaceuticals.  He has more than 25 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rare disease (ACTIMMUNE, RAVICTI, PROCYSBI), autoimmune (HUMIRA), primary care, orthopedic (CELEBREX), diabetes (BYETTA), anti-infectives and cardiovascular spaces.  This includes roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott, (now AbbVie), Amylin and Horizon Pharmaceuticals. Hampton earned his Bachelor of Science from Miami University in Oxford, Ohio.  He serves on the board of IMAC (NASDAQ:  IMAC) regeneration centers, pubic regenerative medicine centers.

CONTACT US

MEDICAL ENQUIRES

[email protected]

INVESTOR RELATIONS ENQUIRES
[email protected]

BUSINESS DEVELOPMENT ENQUIRIES
[email protected]

BUSINESS MEDIA AND ANALYST ENQUIRIES
[email protected]

GENERAL MEDIA ENQUIRIES
[email protected]

GENERAL ENQUIRIES
TEL: +353 1 518 0200

 

Nominated Adviser
Shore Capital and Corporate Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom

Joint Broker
Shore Capital Stockbrokers Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom

Joint Broker
Stifel Nicolaus Europe Limited
150 Cheapside
London, EC2V 6ET
United Kingdom

Euronext Growth Adviser and Joint Broker
J & E Davy
Davy House
49 Dawson Street
Dublin 2
Ireland

Auditors
Grant Thornton
24-26 City Quay
Dublin 2
Ireland

Registrars
Link Asset Services
The Registry
34 Beckenham Road
Kent, BR3 4TU
United Kingdom

Nominated Adviser
Shore Capital and Corporate Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom

Joint Broker
Shore Capital Stockbrokers Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom

Joint Broker
Stifel Nicolaus Europe Limited
150 Cheapside
London, EC2V 6ET
United Kingdom

Euronext Growth Adviser and Joint Broker
J & E Davy
Davy House
49 Dawson Street
Dublin 2
Ireland

Auditors
Grant Thornton
24-26 City Quay
Dublin 2
Ireland

Registrars
Link Asset Services
The Registry
34 Beckenham Road
Kent, BR3 4TU
United Kingdom